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BRIP-1 germline mutation and its role in
colon cancer: presentation of two case
reports and review of literature
Mir Ali* , Celia Dawn Delozier and Uzair Chaudhary
Abstract
Background: Hereditary colon cancer is characterized by the inheritance of an abnormal gene mutation which
predisposes to malignancy. Recent advances in genomic medicine have identified mutations in “novel” genes as
conferring an increased risk of colorectal cancer. Mutations in the BRIP1 gene (BRCA1 Interacting Protein C- terminal
helicase 1) are known to increase the risk of ovarian and breast cancers, but this genes association with colon
cancer has not been previously reported.
Case presentation: We describe two patients with colon cancer whose tumor tissue were found to harbor BRIP1
mutations on analysis by next-generation sequencing. These patients were confirmed by analysis of lymphocytes to
carry the mutation in the germline as well.
Conclusions: These case reports highlight a previously unreported association of BRIP1 germline mutations with
colon cancer predisposition.
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Background
Colon cancer is the third most common cause of
cancer-related mortality in the United States [1]. Be-
tween 2 to 5% of all colon cancers arise in the setting of
well-defined inherited colon cancer syndromes including
Lynch syndrome, Familial adenomatous polyposis, and
MUTYH-associated polyposis. These syndromes are due
to highly penetrant inherited gene mutations. An add-
itional 20% of colorectal cancers are “familial” and likely
linked to alterations in single genes that are less pene-
trant than those associated with well characterized syn-
dromes [2]. Some of these gene mutations associated
with an increased risk of digestive system cancers in-
clude BMPR1A, CDH1, CHEK2, GREM1, POLD1, POLE,
PTEN, SMAD4, TP53. Patients and family members
identified to have these germline mutations have an in-
creased risk of colorectal/digestive system cancers. They
benefit from early screening measures with colonoscopy
and potential monitoring for other cancers associated
with mutations in that specific gene. Similarly, the iden-
tification of additional new pathogenic mutations which
may be involved in the development of colon cancer can
provide us with valuable information for screening and
patient counseling. We present two case reports and
hypothesize that patients with BRIP1 (BRCA1 Interact-
ing Protein C- terminal helicase 1) gene mutations have
an increased risk of colorectal cancer. BRIP1 is a tumor
suppressor gene interacting with another known DNA
repair gene, BRCA-1 (Breast Cancer gene 1), involved in
repair by homologous recombination. Pathogenic germ-
line mutations in BRIP1 are known to confer about 10%
cumulative risk of ovarian cancer and also associated
with an increased risk of female breast cancer [3]. Based
on our literature review, the association of BRIP-1 muta-
tions with colon cancer has not been previously re-
ported. We describe here two patients with colon cancer
who were found to have a BRIP1 mutation in tumor tis-
sue which was subsequently identified in the germline
and postulate that germline BRIP1 mutations confer an
increased risk of colorectal cancer.
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Case presentation
Case report 1
52 y/o female with no significant past medical history
initially presented with left lower quadrant abdominal
pain. Family history includes lung cancer in brother at
age 62 years who had a risk factor of chronic smoking.
Paternal grandmother had bilateral synchronous breast
cancer at the age of 80. Grandfather had prostate cancer
at 79. No family history of gastrointestinal or ovarian
cancer was reported. Pedigree chart for patient’s family
history of cancer is shown below (Figs. 1 and 2). Physical
examination was normal. CT scan of the abdomen showed
an obstructed rectosigmoid mass. Colonoscopy showed
recto sigmoid mass 4.5 × 6.5 cm which was 18 cm from
the anal verge. Biopsy revealed a moderately differentiated
adenocarcinoma. A CT scan of the chest and abdomen
did not show evidence of distant metastases. The patient
underwent laparoscopic rectosigmoid and local lymph
node resection with a left end colostomy. Pathology
showed an invasive, moderately-differentiated adenocar-
cinoma with infiltration beyond the muscularis propria
into subserosal tissue. There were high risk features, in-
cluding lymphovascular, perineural invasion along with six
of twenty-eight lymph nodes positive for adenocarcinoma.
Initial surgical specimen after colectomy was sent for ana-
lysis with next generation sequencing test. Tumor muta-
tions included BRIP1 P619Fs*20: TP53 S2151, splice site
783-2A >G: CDK8 amplification was equivocal and APC
E 1295*. Lynch syndrome screen by immunohistochemis-
try (MLH1, MSH2, MSH6 and PMS2 proteins) showed
normal expression in pathological tissue. There were no
reportable alterations in KRAS, NRAS, and BRAF. The
patient had colon cancer at the relatively young age of 52
with no family history. The patient requested an evalu-
ation of possible hereditary predisposition. Initial testing
with a commercially available 17 gene colon cancer risk
panel was negative. Additional germline testing for BRIP1
gene mutation was proposed based on high allele fre-
quency of BRIP1 mutation in tumor tissue. The patient
was found to be heterozygous for the c.853_1854lnsG
Fig. 1 Family pedigree chart for case report 1
Fig. 2 Pedigree legend for Figs. 1 and 3
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mutation located in coding exon 12 of the BRIP1 gene. No
other germline mutations were identified with the panel
testing used. She was staged as IIIB disease (pT3 pN2a
M0). She was treated with twelve cycles of adjuvant
chemotherapy FOLFOX (5-fluorouracil, leucovorin, oxali-
platin). Six months after finishing chemotherapy, the pa-
tient underwent laparotomy for planned colostomy
reversal. She was found to have intraoperative findings of
metastasis to the omentum and left the ovary. She was
treated with HIPEC surgery (Hyperthermic intraperitoneal
chemotherapy), omentectomy and bilateral salpingo-oo-
phorectomy. She then received eight cycles of chemother-
apy FOLFIRI (5-fluorouracil, Leucovorin, Irinotecan) for
disease recurrence. The patient had another recurrence 1
year later with new pulmonary metastatic disease and
pleural effusion. She was treated with six cycles of chemo-
therapy with FOLFOX and Bevacizumab and currently on
maintenance 5-Fluorouracil and Bevacizumab therapy.
Case report 2
Sixty-two y/o female with a history of uterine fibroid,
hysterectomy and salpingo-oophorectomy underwent
screening colonoscopy which showed 4.9 × 3.4 cm circum-
ferential mass in the proximal ascending colon. The patient
did not have any gastrointestinal complaints of abdominal
pain, constipation or blood in stools. Family history includes
metastatic colon cancer in mother at age 77, maternal aunt
diagnosed with colon cancer at age 50; another maternal
aunt was diagnosed with uterine cancer in her 70’s. Two
cousins on the maternal side had colon cancer at age 50.
Pedigree chart for patient’s family history of cancer is shown
below (Fig. 3). Physical examination was normal. Biopsy of
colon mass showed moderately differentiated adenocarcin-
oma. Staging work up revealed two liver lesions. She under-
went laparoscopic right colectomy and partial hepatectomy.
Surgical specimen after hemicolectomy was sent for
next-generation sequence analysis. Genomic alterations
identified include BRIP1 S988 fs: AKT1 E17K: mTOR
E1799K: APC R1450: CREBBP S889: FAM123B R358:
GNAS R201C: TP53 P177L and 4213Q. No reported alter-
ations in KRAS, NRAS, and BRAF. Lynch syndrome screen
by IHC (MLH1, MSH2, MSH6 and PMS2 proteins) was nor-
mal on the pathological tissue. The patient had a family his-
tory of colon cancer and wanted to be evaluated for gene
mutations associated with hereditary cancer. Initial testing
was done with commercially available 17 gene panel associ-
ated with colon cancer. Further germline testing for BRIP1
gene mutation was done based on high allele frequency of
BRIP1 mutation in tumor tissue. This showed patient was
heterozygous for c.2962deIT pathogenic mutation located in
coding exon 19 of the BRIP1 gene. She was staged as IVA
given metastatic liver disease. She was treated with twelve
cycles of chemotherapy FOLFOX. Two years later she was
found to have a recurrence with liver lesions on PET CT.
She underwent laparoscopic resection of hepatic metastases
followed by adjuvant chemotherapy with eight cycles of
FOLFIRI. Repeat scans did not show any active disease.
Discussion and conclusions
Colorectal cancer (CRC) is the third most frequently di-
agnosed cancer and the second leading cause of cancer
death in the United States [1]. Between 2 to 5% of all
Fig. 3 Family pedigree chart for case report 2 (see Fig. 2 for legend)
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colon cancers arise in the setting of well-defined colon
inherited syndromes whereas another 20% of colon can-
cers are associated with an increased familial incidence
but not following classical transmission patterns. Heredi-
tary Non-Polyposis Colorectal Cancer (HNPCC) or
Lynch syndrome is caused by a mutation in one of the
mismatch repair genes (MSH2, MSH6, PMS2, MLH1,
and EPCAM) and is the most common form of
genetically-determined colon cancer accounting for 2 to
4% of all CRC cases [4]. Familial adenomatosis polyposis
(FAP) and MUTYH associated polyposis are other highly
penetrant gene mutations causing recognizable syn-
dromes. Other moderately penetrant gene mutations for
colorectal cancer (with lifetime risks of cancer between
10 and 50%) include BMPRA1, CHEK2, POLD1, POLE,
PTEN, SMAD4, PTEN, CDH1, and STK11. Patients
found to have these pathogenic mutations along with
personal or family history indicative of increased colon
cancer risk, benefit from earlier or more frequent
screening with colonoscopy and for other malignancies
associated with that particular mutant gene. Information
regarding any genetic mutation may result in a personal-
ized plan for cancer prevention and early detection.
Emerging evidence has identified additional genes that
may be associated with an increased incidence of colon
cancer [12].
Next generation sequence testing (NGS) and
multi-gene “panel” germline mutation testing have pro-
vided tools to help identify additional genes associated
with an increased risk of colon cancer [5]. NGS of tumor
tissue can detect multiple types of genomic alterations,
including nucleotide substitutions, small insertions and
deletions, copy number variations and chromosomal re-
arrangements. NGS will identify mutations useful in
treatment planning, e.g., analyses of KRAS, NRAS, BRAF,
HER2 neu and microsatellite instability (MSI) status all
have implications for treatment decisions. NGS will also
identify additional mutations in tumor tissue whose clin-
ical significance has not been clearly defined. However,
some of the mutations seen in tumor tissue will be con-
stitutional, and might not have been considered in the
etiology of the patient’s tumor. As shown in these two
patients, tumor genomics can help predict the presence
of germline mutations [6]. A new paradigm in cancer
genetics is thus to do paired genomic testing on tumor
and peripheral blood and to consult the results of tumor
genomics when deciding on which genes to test in the
germline.
Both of our patients had risk factors which put them
at higher likelihood of having an inherited cancer syn-
drome and were referred to a medical geneticist for as-
sessment. The first patient had colon cancer diagnosed
at the relatively young age of 52. The second patient had
multiple family members with a history of colon cancer,
albeit mainly at later ages. Both patients were initially
tested for germline mutation with a commercially avail-
able multigene test which evaluates for genes commonly
associated with hereditary colon cancer. These genes in-
clude APC, BMPR1A, CDH1, CHEK2, MLH1, MSH2,
MSH6, MUTYH, PMS2, POLD1, POLE, PTEN, SMAD4,
STK11, TP53, EPCAM, and GREM1. Both patients were
negative for any of the above mutations in lymphocytes.
Further testing was directed based on NGS test results.
Both our patients had NGS testing of tumor tissue
which was negative for KRAS, NRAS, BRAF mutations
and demonstrated microsatellite stability. Our first pa-
tient had mutations in BRIP1, TP53, APC, and CDK8 in
tumor tissue. The second patient had mutations in
AKT1, MTOR, APC, BRIP1, CREBBP, FAM123B, GNAS,
and TP53. Both patients were tested for BRIP1 germline
mutation and were positive for the same pathogenic mu-
tation identified in tumor tissue. The first patient had a
deletion of one nucleotide at position 2962 located in
exon 19 of the BRIP1 gene, causing translational frame-
shift with a predicted alternate stop codon. The second
patient had the insertion of a nucleotide at position 1853
located in coding exon 12 of the BRIP1 gene causing
translational frameshift with a predicted alternate stop
codon. These alterations result in loss of function by
premature protein truncation or mRNA decay. The im-
portance of these germline mutations needs to be inter-
preted based on evidence of their association with the
disease. These BRIP1 mutations have enough evidence
that they are pathogenic to cause an increased risk of
ovarian and breast cancer [7]. Whether these are vari-
ants of unknown significance or pathogenic for colon
cancer itself has yet to be established.
BRCA-1 interacting (BRIP1) gene maps to chromo-
some 17 (17q23.2). It encodes a protein which is a mem-
ber of RecQ DEAH helicase family and interacts with
BRCT repeat of (BRCA1). The bound complex is essen-
tial in the normal double strand break repair function of
the BRCA1 complex. Monoallelic pathogenic germline
mutations in BRIP1 confer up to 10% cumulative risk of
ovarian cancer [7]. Also, BRIP1 mutations are associated
with increased female breast cancer risk [8]. Biallelic
pathogenic mutations in the BRIP1 gene are known to
cause Fanconi anemia type J (FA-J), a rare autosomal re-
cessive disorder affecting multiple body systems. This
syndrome is characterized by marrow failure and vari-
able presentation of anomalies, including short stature,
abnormal skin pigmentation, abnormal thumbs, malfor-
mations of the skeletal central nervous systems, and de-
velopmental delay. We propose a pathogenic role of
BRIP-1 in causing colon cancer. BRIP1 mutations have
been reported in 3% of the colon cancer tissue samples
analyzed in the colorectal adenocarcinoma TCGA (The
cancer genome atlas) dataset [9]. There have also been
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studies where BRIP1 has shown to be a factor in deter-
mining the recurrence rate in colon cancer. A 31 gene
molecular signature which included BRIP1 was devel-
oped using logistic regression analysis, and its presence
was associated with increased recurrence of colon cancer
[10]. It may be relevant that both patients here had re-
currences. The increased BRIP1 expression had been im-
plicated in resistance to 5-fluorouracil treatment [11]. We
hypothesize that germline BRIP1 mutation was a factor in
the etiology of the colon cancers in our patients.
There are current clinical implications of having tested
positive for BRIP1 germline pathogenic mutation.
National comprehensive cancer network (NCCN) rec-
ommends consideration of prophylactic salpingo-oo-
phorectomy to decrease the risk of developing ovarian
cancer. Based on current evidence, this surgery should
be considered around age 50–55 [11], The current
NCCN guidelines do not recommend additional breast
cancer screening for individuals with a single pathogenic
BRIP1 variant but caution that management should ul-
timately be guided by personal and family history. In our
opinion patients who have BRIP1 mutation may poten-
tially benefit from earlier or more frequent screening
with colonoscopy, especially with family history of colon
cancer. NCCN recognized the role of newly identified
genes that may be associated with an increased risk of
colon cancer [12]. Our case reports suggest that BRIP1
is another similar gene which may have a causative role
in colon cancer. Larger studies will provide more evi-
dence to ascertain if this association is strong. This in-
formation can be obtained with the addition of the
BRIP1 gene to research level panels evaluating germline
mutations and colon cancer predisposition. In conclu-
sion, our case reports suggest that germline BRIP1 mu-
tation may be associated with colon cancer
predisposition and should be further investigated.
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